Novel strategies in immunosuppression: Issues in perspective

Transplantation

Volumn 91, Issue 10, 2011, Pages 1057-1064

  Webber, Allison ^a   Hirose, Ryutaro ^a   Vincenti, Flavio ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biologics; Immunosuppression; Tolerance

Indexed keywords

ABATACEPT; ALEFACEPT; ASKP 1240; ATACICEPT; B7 ANTIGEN; BELATACEPT; BELIMUMAB; BORTEZOMIB; CALCINEURIN INHIBITOR; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CHI 220; ECULIZUMAB; EFALIZUMAB; IMMUNOGLOBULIN; JANUS KINASE INHIBITOR; LUCATUMUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HU5C8; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PG 102; PLACEBO; PRO 64553; RAPAMYCIN; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY; TOFACITINIB; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CAPILLARITIS; CELL ACTIVATION; CELL SURVIVAL; DRUG BINDING; DRUG MECHANISM; DRUG POTENTIATION; DRUG WITHDRAWAL; ENZYME INHIBITION; GLOMERULITIS; GLOMERULOPATHY; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; NEPHROTOXICITY; NEUROPATHY; OUTCOME ASSESSMENT; PLASMA CELL; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RISK FACTOR; THROMBOEMBOLISM; VIRUS INFECTION;

ANIMALS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79955590004     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182145306     Document Type: Review

References (83)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
2. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
3. Gourishankar S, Leduc R, Connett J, et al. Pathological and clinical characterization of the "troubled transplant": Data from the DeKAF study. Am J Transplant 2010; 10: 324.
4. Matas AJ, Leduc R, Rush D, et al. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses ofCANor CR: Preliminary data from the DeKAF study. Am J Transplant 2010; 10: 315.
5. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibodymediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68.
6. Einecke G, Halloran PF. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure: Response to Dr. Loupy et al. Am J Transplant 2010; 10: 953.
7. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532.
8. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063.
9. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505.
10. Opelz G, Dohler B. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009; 87: 795.
11. Curtis JJ. Hypertension following kidney transplantation. Am J Kidney Dis 1994; 23: 471.
12. Curtis JJ. Hypertensinogenic mechanism of the calcineurin inhibitors. Curr Hypertens Rep 2002; 4: 377.
13. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63: 331.
14. Luke RG. Mechanism of cyclosporine-induced hypertension. Am J Hypertens 1991; 4(5 Pt 1): 468.
15. Abramowicz D, Del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16: 2234.
16. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: The "creeping creatinine" study. Transplantation 2005; 79: 466.
17. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
18. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
19. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282.
20. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070.
21. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514.
22. Pearson Tea. An MMF based regimen in combination with sirolimus after CNI withdrawal in renal transplant recipients: Final results of the Spare the Nephron Trial. [Abstract]. Am J Transplant 2008; 8: 213.
23. Schold JD, Santos A, Rehman S, et al. The success of continued steroid avoidance after kidney transplantation in the US. Am J Transplant 2009; 9: 2768.
24. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564.
25. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89: 1.
26. Cosio FG, Grande JP, Wadei H, et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464.
27. Haririan A, Kiangkitiwan B, Kukuruga D, et al. The impact of c4d pattern and donor-specific antibody on graft survival in recipients requiring indication renal allograft biopsy. Am J Transplant 2009; 9: 2758.
28. Sis B, Jhangri GS, Bunnag S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312.
29. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346.
30. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
31. Jordan SC, Toyoda M, Vo AA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009; 88: 1.
32. Becker YT, Becker BN, Pirsch JD, et al. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996.
33. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124.
34. Perry DK, Pollinger HS, Burns JM, et al. Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant 2008; 8: 133.
35. Bossen C, Schneider P. BAFF, APRIL and their receptors: Structure, function and signaling. Semin Immunol 2006; 18: 263.
36. Cheema GS, Roschke V, Hilbert DM, et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313.
37. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 2453.
38. Zhang J, Roschke V, Baker KP, et al. Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6.
39. Ramanujam M, Wang X, Huang W, et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006; 116: 724.
40. Dall'Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase Ib, doubleblind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56: 4142.
41. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201.
42. Everly JJ, Walsh RC, Alloway RR, et al. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009; 14: 662.
43. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 277.
44. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010; 10: 681.
45. Lonze BE, Dagher NN, Simpkins CE, et al. Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. Am J Transplant 2010; 10: 2154.
46. Wahrmann M, Haidinger M, Kormoczi GF, et al. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010; 89: 1385.
47. Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25: 1256.
48. Chatelet V, Fremeaux-Bacchi V, Lobbedez T, et al. Safety and longterm efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009; 9: 2644.
49. Davin JC, Gracchi V, Bouts A, et al. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 2010; 55: 708.
50. Nurnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 542.
51. Zimmerhackl LB, Hofer J, Cortina G, et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010; 362: 1746.
52. Lonze BE, Dagher NN, Locke JE, et al. Complement inhibitors for treatment of antibody-mediated renal allograft injury [Abstract]. Am J Transplant 2010; 10: 564.
53. Stegall MD, Diwan TS, Cornell LD, et al. Terminal complement inhibition decreases early acute humoral rejection in sensitized renal transplant recipients [Abstract]. Am J Transplant 2010; 10: 39.
54. Cornell LD, Gloor JD, Nasr SH, et al. Chronic humoral rejection despite C5 inhibition after positive-crossmatch kidney transplantation [Abstract]. Am J Transplant 2010; 10: 125.
55. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547.
56. Vincenti F. Chronic induction. What's new in the pipeline. Contrib Nephrol 2005; 146: 22.
57. Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J AmSoc Nephrol 2010; 21: 1587.
58. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535.
59. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770.
60. Vincenti F, Silva HT, Busque S, et al. A phase 2B study of CNI-free immunosuppression with the JAK inhibitor CP-690-550 in de novo kidney transplant patients: 6-month interim analysis [Abstract]. Am J Transplant 2010; 10: 211.
61. Busque S, Leventhal J, Brennan DC, et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: A pilot study in de novo kidney allograft recipients. Am J Transplant 2009; 9: 1936.
62. Vincenti F, Kirk AD. What's next in the pipeline. Am J Transplant 2008; 8: 1972.
63. Kirk AD, Knechtle SJ, Sollinger HE, et al. Preliminary results of the use of humanized anti-CD 154 in human renal allotransplantation [Abstract]. Am J Transplant 2001; 1(suppl 1): 191.
64. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002; 8: 247.
65. Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004; 13: 391.
66. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789.
67. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
68. Nicolls MR, Gill RG. LFA-1 (CD11a) as a therapeutic target. Am J Transplant 2006; 6: 27.
69. Ortonne JP, Lebwohl M, Em Griffiths C. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol 2003; 13: 117.
70. Kirk A, Weaver T, Charafeddine A, et al. Targeting of costimulation blockade resistant T effector memory (TEM) cells in non-human primate renal transplantation with LFA-3-Ig (alefacept) prolongs allograft survival [Abstract]. Am J Transplant 2008; 8(suppl 2): 204.
71. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887.
72. Augustine JJ, Siu DS, Clemente MJ, et al. Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant 2005; 5: 1971.
73. Heeger PS, Greenspan NS, Kuhlenschmidt S, et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999; 163: 2267.
74. Jones DL, Sacks SH, Wong W. Controlling the generation and function of human CD8 memory T cells in vitro with immunosuppressants. Transplantation 2006; 82: 1352.
75. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248.
76. Feguson R, Vincenti F, Kaufman DB, et al. Immunosuppression with a belatacept-based, CNI avoiding and steroid-avoiding regimen vs tacrolimus-based, steroid avoiding regimen in kidney transplant patients: Results of a 1-year, randomized study. Am J Transplant. 2011; 11: 76.
77. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358: 353.
78. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358: 362.
79. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663.
80. Trivedi HL, Terasaki PI, Feroz A, et al. Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients. Transplantation 2010; 90: 221.
81. Ott HC, Matthiesen TS, Goh SK, et al. Perfusion-decellularized matrix: Using nature's platform to engineer a bioartificial heart. Nat Med 2008; 14: 213.
82. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861.
83. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917.